INTRODUCTION
Circulating platelets are exposed to diverse tissue-releasing substances (1) and play a pivotal role in haemostasis and thrombosis (2). When platelets are activated by agonists such as adenosine diphosphate (ADP), U46619 (9, 11-dieoxy-11α, 9α-methanoepoxyprostaglandin Fα; thromboxane A2 mimetic), collagen, or thrombin, they aggregate and release their granule contents. Secreted granule contents such as ATP, ADP, serotonin, and calcium ion from dense granules as well as TXA2 formation are essential for the induction of secondary platelet aggregation (3, 4). The majority of platelet agonists are also known to activate phosphoinositol-3 kinase (PI3K) in platelets, and inhibitors of PI3K block fibrinogen binding and platelet aggregation. The lack of phosphorylated Akt, one of the major downstream effectors of the PI3K pathway, was reported to cause impaired platelet aggregation (5).
Epinephrine (epinephrine) induces heterogeneous responses on human platelets. Impaired responsiveness of platelets to epinephrine and other catecholamines (CA) has been reported in approximately 20% of samples from healthy normal Korean and Japanese individuals (6, 7). The degrees of aggregation in response to other aggregation-inducing agents (AA, ADP, and U46619) are also significantly lower in platelets that are hyporesponsive to CA (8, 9). Elevated plasma concentrations of NO and cGMP have been observed in CA-hypo-responders (CA-HY) compared to CA-good responders (CA-GR) (10).
In this study, use of a widely used PKC inhibitor, RO 31-8220 (RO) increased epinephrine-induced platelet aggregation in platelet-rich plasma (PRP) from CA-GR. In addition, RO induced platelet aggregation in epinephrine-stimulated PRP from CA-HY, who are normally characterized by impaired platelet aggregation. The present study was undertaken to understand the effect of RO on epinephrine-stimulated human platelet aggregation and especially to identify the mechanism of their upregulatory effect on epinephrine-induced PRP from CA-HY.
RESULTS

RO 31-8220 and Gö 6983 potentiate platelet aggregation
The effects of five different commercially available PKC inhibitors were investigated on epinephrine-induced platelet aggregation in PRP obtained from both CA-GR and CA-HY. As shown in Fig. 1A and 1B, two PKC inhibitors, RO 31-8220 (RO), a non-selective inhibitor, and Gö 6983 (Gö), a PKC α, β, δ, γ, and ζ inhibitor, potentiated 0.1 uM epinephrine-induced platelet aggregation in PRP from CA-GR in a dose-dependent manner; RO and Gö alone did not induce platelet aggregation. Moreover, both RO and Gö induced platelet aggregation in 1 uM epinephrine-treated PRP from CA-HY. Normally, epi-http://bmbreports.org BMB reports nephrine (1-100 uM) alone fails to induce aggregation in PRP from CA-HY (6, 7). On the other hand, RO and Gö suppressed platelet aggregation induced by PMA, a PKC activator, in PRP from both groups. In contrast, RO and Gö presented neither potentiatory nor inhibitory effects on other agonists such as ADP, collagen, and U46619, a TXA2 mimic, although U46619-stimulated aggregation in the presence of aspirin was inhibited by RO (data not shown), as previously reported (11). Rottlerin (a PKC δ inhibitor) and Gö 6976 (a PKC α and β inhibitor) did not augment epinephrine-induced aggregation but rather inhibited the extent of aggregation in PRP from CA-GR (Fig. 1C) .
Effect of RO 31-8220 and Gö 6983 on platelet aggregation is blocked by wortmannin
The effect of wortmannin, a PI3K inhibitor, was evaluated on epinephrine-induced as well as RO or Gö-potentiated platelet aggregation to determine the involvement of the PI3K pathway. Epinephrine (1 uM)-induced platelet aggregation in PRP from CA-GR was be inhibited by the addition of wortmannin (10 uM), as shown in Fig. 2A . Epinephrine (0.1 or 1 uM)-induced aggregation potentiated by either RO or Gö was also suppressed by wortmannin in PRP from both CA-GR and CA-HY ( Fig. 2A and B) .
RO 31-8220 and Gö 6983 augment phosphorylation of Akt
The effect of RO or Gö on the level of phosphorylated Akt, the major downstream effector of PI3K, in PRP was evaluated. In PRP from CA-GR, epinephrine upregulated phosphorylation of Akt, whereas no detectable effects were observed with either RO or Gö alone ( Fig. 3A and B) . In PRP from CA-HY, neither epinephrine, RO, nor Gö induced phosphorylation of Akt. However, the level of phosphorylated Akt was increased upon the addition of either RO or Gö in epinephrine-stimulated PRP from both groups, as shown in Fig. 3A , B and C.
RO 31-8220 or Gö 6983 increases ATP secretion
The level of secreted ATP was measured to determine the effects of RO and Gö on granule secretion during platelet aggregation. ATP was not detected in either 0.1 uM epinephrine-stimulated PRP from CA-GR or 1 uM epinephrinestimulated PRP from CA-HY, whereas negligible platelet aggregation was observed ( Fig. 4A and B) . Secretion of ATP was increased by RO and Gö in 0.1 uM epinephrine-stimulated PRP from both CA-GR (0.10 ± 0.04 and 0.11 ± 0.03 nmol, respectively) and 1 uM epinephrine-stimulated PRP from CA-HY (0.42 ± 0.04 and 0.13 ± 0.08 nmol, respectively), and the degree of platelet aggregation was approximately equal to that of full platelet aggregation in 1 uM epinephrine-stimulated PRP from CA-GR. However, the amount of secreted ATP was much lower than that (1.66 ± 0.07 nmoles) observed in 1 uM epinephrine-stimulated PRP from CA-GR.
RO 31-8220 and Gö 6983 potentiate TXA2 formation
TXA2 generation is essential for the induction of secondary platelet aggregation. The effects of RO or Gö on TXA2 production were observed during platelet aggregation. The formation of TXA2 was determined by measuring TXB2, the stable metabolite of TXA2. As shown in Fig. 4C , TXA2 production was increased by the addition of 1 uM epinephrine to PRP from CA-GR, whereas TXA2 formation was negligibly increased compared to control platelets in 0.1 uM epinephrine-stimulated PRP from both CA-GR and 1 uM epinephrine-stimulated PRP from CA-HY. Upon addition of RO or Gö, TXA2 formation was enhanced in 0.1 uM epinephrine-activated PRP from both CA-GR (141.32 ± 0.3550 or 146.32 ± 0.0135 vs 46.321 ±
